

Pablo Gajate

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/75024/publications.pdf>

Version: 2024-02-01

36
papers

933
citations

840776

11
h-index

477307

29
g-index

36
all docs

36
docs citations

36
times ranked

1137
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114.	27.0	427
2	Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. <i>Cancer Treatment Reviews</i> , 2017, 58, 41-50.	7.7	104
3	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	3.1	52
4	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1 refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	51
5	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	1.6	49
6	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. <i>Future Oncology</i> , 2017, 13, 615-624.	2.4	32
7	Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 542-542.	1.6	30
8	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). <i>Oncologist</i> , 2020, 25, 745-e1265.	3.7	25
9	Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5014-5014.	1.6	23
10	Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments. <i>European Journal of Cancer</i> , 2022, 166, 229-239.	2.8	17
11	Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature. <i>Frontiers in Pharmacology</i> , 2022, 13, 774170.	3.5	15
12	Emerging use of everolimus in the treatment of neuroendocrine tumors. <i>Cancer Management and Research</i> , 2017, Volume 9, 215-224.	1.9	14
13	Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4521-4521.	1.6	13
14	Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. <i>Oncologist</i> , 2021, 26, 941-949.	3.7	12
15	Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms. <i>Clinical and Translational Oncology</i> , 2018, 20, 561-569.	2.4	10
16	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. <i>Biomedicines</i> , 2022, 10, 537.	3.2	9
17	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 515-524.	4.5	9
18	Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. <i>Clinical and Translational Oncology</i> , 2021, 23, 882-891.	2.4	5

#	ARTICLE	IF	CITATIONS
19	The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of the combination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve to systemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4105-4105.	1.6	5
20	Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH "Grupo Centra"™ of Genitourinary Tumors. <i>Kidney Cancer</i> , 2019, 3, 177-182.	0.4	4
21	Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on <i>FGFR</i> mRNA overexpression.. <i>Journal of Clinical Oncology</i> , 2020, 38, 527-527.	1.6	4
22	Successful rapid desensitization to Atezolizumab in delayed hypersensitivity confirmed with Lymphocyte Transformation Test.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	3.8	4
23	Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS503-TPS503.	1.6	3
24	Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma. <i>Autopsy and Case Reports</i> , 2018, 8, e2018005.	0.6	3
25	Direct impact of clinical research in metastatic renal cell carcinoma (mRCC): A cost-effectiveness analysis of patient care outcomes and cost savings in a real-life scenario of a large public university hospital in Spain.. <i>Journal of Clinical Oncology</i> , 2019, 37, 637-637.	1.6	3
26	Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 546-546.	1.6	3
27	Real-World Outcome of 173 Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC) Cases: The Experience of the Center Group for Genitourinary Tumors. <i>Kidney Cancer</i> , 2019, 3, 41-50.	0.4	2
28	Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study. <i>European Thyroid Journal</i> , 2022, 11, .	2.4	2
29	How do patterns of progression influence treatment selection after chemohormonal therapy in patients with metastatic hormone sensitive prostate cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, e16504-e16504.	1.6	1
30	Interim analysis of ibrutinib plus paclitaxel for patients with metastatic urothelial carcinoma previously treated with platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 365-365.	1.6	1
31	Practice change in the management of metastatic urothelial carcinoma after ASCO 2020. <i>World Journal of Clinical Oncology</i> , 2020, 11, 976-982.	2.3	1
32	Cirugía en las metástasis pancreáticas por carcinoma renal. <i>Cirugía Española</i> , 2020, 100, 50-50.	0.2	0
33	Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case Report. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.3	0
34	Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4522-4522.	1.6	0
35	CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS770-TPS770.	1.6	0
36	Surgery of pancreatic metastasis from renal cell carcinoma. <i>Cirugía Española (English Edition)</i> , 2022, 100, 50-52.	0.1	0